These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23406827)

  • 41. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses.
    Houghton M
    Immunol Rev; 2011 Jan; 239(1):99-108. PubMed ID: 21198667
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Challenges and Promise of a Hepatitis C Virus Vaccine.
    Cox AL
    Cold Spring Harb Perspect Med; 2020 Feb; 10(2):. PubMed ID: 31548228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospects for a vaccine against the hepatitis C virus.
    Houghton M; Abrignani S
    Nature; 2005 Aug; 436(7053):961-6. PubMed ID: 16107836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus.
    Vang L; Morello CS; Mendy J; Thompson D; Manayani D; Guenther B; Julander J; Sanford D; Jain A; Patel A; Shabram P; Smith J; Alexander J
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009195. PubMed ID: 33711018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and protective efficacy of virus-like particles and recombinant fiber proteins in broiler-breeder vaccination against fowl adenovirus (FAdV)-8b.
    Gupta A; Ahmed KA; Ayalew LE; Popowich S; Kurukulasuriya S; Goonewardene K; Gunawardana T; Karunarathna R; Ojkic D; Tikoo SK; Willson P; Gomis S
    Vaccine; 2017 May; 35(20):2716-2722. PubMed ID: 28396209
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current progress in development of hepatitis C virus vaccines.
    Liang TJ
    Nat Med; 2013 Jul; 19(7):869-78. PubMed ID: 23836237
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Viral evasion and challenges of hepatitis C virus vaccine development.
    Pierce BG; Keck ZY; Foung SK
    Curr Opin Virol; 2016 Oct; 20():55-63. PubMed ID: 27657659
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficient self-assembly and protective efficacy of infectious bursal disease virus-like particles by a recombinant baculovirus co-expressing precursor polyprotein and VP4.
    Lee HJ; Kim JY; Kye SJ; Seul HJ; Jung SC; Choi KS
    Virol J; 2015 Oct; 12():177. PubMed ID: 26502988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DNA vaccine expressing the non-structural proteins of hepatitis C virus diminishes the expression of HCV proteins in a mouse model.
    Wada T; Kohara M; Yasutomi Y
    Vaccine; 2013 Dec; 31(50):5968-74. PubMed ID: 24144476
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genital delivery of virus-like particle and pseudovirus-based vaccines.
    Cuburu N; Chackerian B
    Expert Rev Vaccines; 2011 Sep; 10(9):1245-8. PubMed ID: 21919611
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of humoral and cellular immune responses against hepatitis C virus by vaccination with replicon particles derived from Sindbis-like virus XJ-160.
    Zhu W; Fu J; Lu J; Deng Y; Wang H; Wei Y; Deng L; Tan W; Liang G
    Arch Virol; 2013 May; 158(5):1013-9. PubMed ID: 23250650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current status and future directions of fish vaccines employing virus-like particles.
    Jeong KH; Kim HJ; Kim HJ
    Fish Shellfish Immunol; 2020 May; 100():49-57. PubMed ID: 32130976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Virus-like particles in picornavirus vaccine development.
    Dong H; Guo HC; Sun SQ
    Appl Microbiol Biotechnol; 2014 May; 98(10):4321-9. PubMed ID: 24647496
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice.
    Gummow J; Li Y; Yu W; Garrod T; Wijesundara D; Brennan AJ; Mullick R; Voskoboinik I; Grubor-Bauk B; Gowans EJ
    J Virol; 2015 Aug; 89(15):7991-8002. PubMed ID: 26018154
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Virology of hepatitis C virus].
    Hofmann H
    Wien Med Wochenschr; 2000; 150(23-24):463-6. PubMed ID: 11205175
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus.
    Torresi J; Johnson D; Wedemeyer H
    J Hepatol; 2011 Jun; 54(6):1273-85. PubMed ID: 21236312
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus.
    Feinstone SM; Hu DJ; Major ME
    Clin Infect Dis; 2012 Jul; 55 Suppl 1():S25-32. PubMed ID: 22715210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Virus-like particles in vaccine development.
    Roldão A; Mellado MC; Castilho LR; Carrondo MJ; Alves PM
    Expert Rev Vaccines; 2010 Oct; 9(10):1149-76. PubMed ID: 20923267
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity.
    Zhang W; Dai W; Zhang C; Zhou Y; Xiong P; Wang S; Ye X; Liu Q; Zhou D; Huang Z
    Emerg Microbes Infect; 2018 May; 7(1):94. PubMed ID: 29777102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles.
    Lin YL; Yu CI; Hu YC; Tsai TJ; Kuo YC; Chi WK; Lin AN; Chiang BL
    Vaccine; 2012 Feb; 30(7):1305-12. PubMed ID: 22214888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.